Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

Knowledge and Awareness of HPV Vaccine and Acceptability to Vaccinate in Sub-Saharan Africa: A Systematic Review

Knowledge and Awareness of HPV Vaccine and Acceptability to Vaccinate in Sub-Saharan Africa: A Systematic Review

  • Stacey Perlman, 
  • Richard G. Wamai, 
  • Paul A. Bain, 
  • Thomas Welty, 
  • Edith Welty, 
  • Javier Gordon Ogembo
PLOS
x
  • Published: March 11, 2014
  • DOI: 10.1371/journal.pone.0090912

Abstract

Objectives

We assessed the knowledge and awareness of cervical cancer, HPV and HPV vaccine, and willingness and acceptability to vaccinate in sub-Saharan African (SSA) countries. We further identified countries that fulfill the two GAVI Alliance eligibility criteria to support nationwide HPV vaccination.

Methods

We conducted a systematic review of peer-reviewed studies on the knowledge and awareness of cervical cancer, HPV and HPV vaccine, and willingness and acceptability to vaccinate. Trends in Diphtheria-tetanus-pertussis (DTP3) vaccine coverage in SSA countries from 1990–2011 were extracted from the World Health Organization database.

Findings

The review revealed high levels of willingness and acceptability of HPV vaccine but low levels of knowledge and awareness of cervical cancer, HPV or HPV vaccine. We identified only six countries to have met the two GAVI Alliance requirements for supporting introduction of HPV vaccine: 1) the ability to deliver multi-dose vaccines for no less than 50% of the target vaccination cohort in an average size district, and 2) achieving over 70% coverage of DTP3 vaccine nationally. From 2008 through 2011 all SSA countries, with the exception of Mauritania and Nigeria, have reached or maintained DTP3 coverage at 70% or above.

Conclusion

There is an urgent need for more education to inform the public about HPV, HPV vaccine, and cervical cancer, particularly to key demographics, (adolescents, parents and healthcare professionals), to leverage high levels of willingness and acceptability of HPV vaccine towards successful implementation of HPV vaccination programs. There is unpreparedness in most SSA countries to roll out national HPV vaccination as per the GAVI Alliance eligibility criteria for supporting introduction of the vaccine. In countries that have met 70% DTP3 coverage, pilot programs need to be rolled out to identify the best practice and strategies for delivering HPV vaccines to adolescents and also to qualify for GAVI Alliance support.

Introduction

The introduction of vaccines has been one of the most effective public health interventions for combating infectious diseases [1], [2]. The establishment of the Expanded Programme on Immunization (EPI) in 1974 by the World Health Organization (WHO) led to the global eradication of smallpox and has greatly reduced the burden of several infectious diseases, including poliomyelitis, measles, tuberculosis, tetanus and diphtheria in many parts of the world [2]. Despite slow progress in increasing vaccine access and immunization coverage, the EPI has reported 83% coverage of infants worldwide of the three doses of Diphtheria-tetanus-pertussis (DTP3) vaccine in 2011, similar to coverage in 2009 (82%) and 2010 (85%) [1], [3]. Expansion and delivery of life-saving vaccines in the 2010–2020 “decade of vaccines” is expected to save 6.4 million lives, valued at hundreds of billions of dollars in low and middle-income countries [4]. Currently, DTP3 coverage by age 12 months is a key indicator of immunization program performance of a country and is associated with the level of capacity to effectively manage and deliver a new vaccine to a target cohort [5], [6].

Worldwide, 15% of all cancer cases and nearly 26% of cancer cases in developing countries are attributable to infectious agents, particularly viruses [7]. Cervical cancer, which is caused by the human papillomavirus (HPV), is the leading cause of cancer mortality among women in sub-Saharan Africa (SSA) [8], [9]. The approval and recommendation of two vaccines – Gardasil and Cervarix – provide a huge opportunity to curb the burden of cervical cancer [10]. As one of the key strategies in preventing cervical cancer in developed countries, providing HPV vaccines in low and middle income countries is a critical pillar for meeting the global action plan for closing the cancer divide [5]. However, outstanding barriers to achieving this goal in low-income countries remain. These include high cost of vaccine and vaccine delivery [11], low cervical cancer screening levels [12], poor health system capabilities [11], [13], inaccessibility to medical care [14], low awareness and knowledge of HPV and cervical cancer[14][18], and failure of cervical cancer to be recognized as a major health concern [19].

Several recent developments have emphasized HPV vaccine as an important prevention strategy. The 2009 WHO position paper on HPV vaccines recommended they be included in routine national immunization programs as a public health priority [20]. Furthermore, one of the goals of the 2006 Global Immunization Vision and Strategy (GIVS) is to introduce new vaccines to all eligible populations within five years of introduction in national programs [3]. Additionally, major milestones during 2007–2011 have brought access to HPV vaccines within reach for many adolescents in low-income countries. In May 2013, for the first time ever, a public offer was made by GAVI Alliance for a price of $4.50 per dose for both Gardasil and Cervarix to low-income countries [21], a drastic reduction from $360 for the required three doses [22], [23].

Currently, the GAVI Alliance uses two criteria to determine eligibility for vaccination support, including HPV vaccine: 1) a DTP3 threshold of 70% national coverage (WHO/UNICEF estimates) and 2) a pilot demonstration of the ability to deliver a complete multi-dose series of vaccines to at least 50% of the target vaccination cohort in an average sized district in a country [24]. Recently, Rwanda was the first country to take advantage of the low pricing through a partnership with pharmaceutical manufacturer Merck, achieving 93% coverage of HPV vaccination of all grade six adolescent girls in 2011 [25][27], which is, to the best of our knowledge, the highest in the world. Through other sources of subsidized HPV vaccines, 88.9% of girls were fully vaccinated in Uganda using a school-based pilot program supported by PATH International in 2009 [28]. A similar HPV vaccination pilot initiative was recently undertaken in Cameroon [15], Tanzania [29], Lesotho [30] and South Africa [31]. More recently, Kenya became the first SSA country to receive GAVI Alliance support to roll out a HPV vaccine pilot project (see: http://www.gavialliance.org/support/nvs/​human-papillomavirus-vaccine-support). GAVI Alliance also announced that in 2014 it will support the first nationwide introduction of HPV vaccine in Rwanda for girls of all eligible ages, as well as other HPV demonstration projects in Mozambique, Zimbabwe, Ghana, Madagascar, Malawi, Niger, Sierra Leone, and Tanzania (see: http://www.gavialliance.org/support/nvs/​human-papillomavirus-vaccine-support).

These developments, coupled with SSA's recent success in reaching 70% coverage for other routine vaccines, namely measles, hepatitis B, Influenza, tuberculosis and polio since 1990 [3], provide strong evidence of how introducing HPV vaccine can be achieved in other countries meeting the GAVI Alliance eligibility criteria. The success of pilot demonstrations in Rwanda, South Africa, Cameroon, Lesotho, Tanzania and Uganda also provide lessons on how to design and implement national HPV vaccination programs tailored for a specific group of individuals in resource-limited regions.

Nevertheless, introducing HPV vaccine in SSA offers unique challenges, especially due to limited awareness of cervical cancer, its relationship to HPV, concerns about safety and future fertility, and political factors [32], as seen in recent cases in Rwanda [26], [27] and Cameroon [33]. These unsubstantiated rumors about side effects or adverse outcomes that may not be casually related to the vaccine may negatively impact public trust and adversely impact HPV immunization programming leading to suspension of the program altogether as recently experienced in Japan [34] and India [35].

In this study, we assessed the knowledge and awareness of cervical cancer, HPV and HPV vaccine, willingness and acceptability to vaccinate through a systematic review of peer-reviewed literature. We further identified the fulfillment of GAVI Alliance eligibility criteria among countries in SSA. To the best of our knowledge this is the first systematic review of the potential readiness for introduction of HPV vaccine in the sub-continent, which reveals further insight into some of the unique challenges that need to be addressed.

Methods

Identification of Studies

Studies examining awareness, knowledge of cervical cancer, HPV and acceptability of HPV vaccines in SSA were identified by searching PubMed/MEDLINE (NCBI), Embase (Elsevier), African Index Medicus (AIM), and POPLINE (K4Health) from their earliest dates through July 11, 2013. Bibliographies of relevant reviews and eligible studies were examined for additional sources. The search was performed by a librarian (PAB) using terms for papillomavirus vaccines and vaccination, acceptability or awareness, and the names of all SSA countries (Appendix S1). The search was conducted without language restriction. Titles and abstracts of identified articles were reviewed by two authors (SP and JGO) and categorized as relevant using the criteria outlined below.

The review was conducted using methodology reported in the National Health Service Centre for Reviews and Dissemination report, supplemented by Harden's recommendations for systematic reviews of qualitative studies [36]. We also adhered to guidance on methods for conducting and reporting systematic reviews in the PRISMA statement where it could be applied to mixed method reviews [37]. Two authors (JGO and RGW) appraised the quality of the studies using a checklist developed by the National Institute for Health and Clinical Excellence [38], and surveys using a checklist adapted from Pettigrew and Roberts [39] provided in supplementary Table 1 and Table 2, respectively.

thumbnail
Table 1. A summary of countries included in the systematic review.

doi:10.1371/journal.pone.0090912.t001

thumbnail
Table 2. Overview of knowledge and awareness of HPV, cervical cancer and HPV vaccine, willingness to vaccinate, and acceptability of HPV vaccine in sub-Saharan Africa*.

doi:10.1371/journal.pone.0090912.t002

Inclusion Criteria

Studies included in the review needed to meet the following criteria: 1) it occurred in a SSA country; 2) it was published in 2006 or later, after HPV vaccination was introduced; 3) it focused on one or more of the three key demographics (adolescents, parents/guardians, healthcare workers); and 4) it examined at least one or more of the following key themes: a) level of awareness of HPV and/or cervical cancer; b) level of knowledge of cervical cancer and/or awareness; c) willingness to vaccinate; d) and acceptability of HPV vaccine. Studies that conducted a pilot HPV vaccination program were automatically included in the review. Animal studies were excluded from the review.

Article Review

A systematic review of the identified studies was then performed summarizing key results. The authors' findings were treated as primary data and studies were synthesized using a framework approach. Data were extracted and organized by key information such as demographic, method and sample size, and key findings of the study about levels of knowledge, awareness, willingness and acceptability. Any strategies for vaccination or increasing awareness (whether recommended or implemented strategies) were also extracted along with factors influencing acceptability of HPV vaccine.

Analysis

Levels of awareness, knowledge, acceptability and willingness were broken down into these categories: 1) awareness of cervical cancer, HPV and/or HPV vaccine; 2) knowledge of cervical cancer, HPV and/or HPV vaccine; 3) acceptability of HPV vaccine (and in one case, acceptability of cervical cancer screening); and 4) willingness to vaccinate or get vaccinated. Willingness was broken down further into categories based on how each individual article defined it as seen in Table 1. Levels of awareness, knowledge, acceptability and willingness to vaccinate were summarized based on how each individual study categorized the levels (high, low or moderate). The articles were then tallied for each relevant category. Some articles had multiple levels of awareness and knowledge, resulting in one article being counted more than once (i.e. one article may have high awareness of cervical cancer but low awareness of HPV). Strategies for vaccination/increasing awareness and factors influencing acceptability provided qualitative insight and allowed us to identify important themes for awareness, implementation and acceptability of HPV vaccination.

Results

Overview of Studies Examined

The literature search returned 142 unique records as summarized in the flow chart (Fig. S1). Review of selected article bibliographies uncovered 10 other articles. A total of 124 relevant articles were selected and reviewed and 29 articles based on 27 studies in 13 different SSA countries met the inclusion criteria. Ten studies focused on women, with ages ranging from 12 to 84, eight studies focused on medical professionals, five focused on parents and six focused on girls in primary schools. Six countries implemented HPV vaccination pilot programs (Cameroon, Lesotho, Rwanda, South Africa, Tanzania and Uganda). Table 1 shows a detailed summary of identified studies and Table 2 summarizes the key findings from each study.

Study Quality

Two qualitative studies were considered to be of good standard while one was considered moderate and one was considered poor. Nearly all of the surveys were well conducted and 17 of these had a sample size greater than 200 respondents. Sixteen of those had a response rate greater than 70%. The remaining studies varied in quality from moderately good to poor [30].

Awareness and Knowledge of Cervical Cancer and HPV

Fifteen studies examined awareness of cervical cancer, HPV and/or HPV vaccine among specific demographic groups. Levels of awareness were mixed with 11 studies demonstrating high awareness, nine studies demonstrating low awareness and two studies demonstrating moderate awareness. Levels of knowledge of cervical cancer and HPV were consistently low. Of the 16 studies examining knowledge of cervical cancer, HPV and HPV vaccine, all noted low levels of knowledge, three reported no knowledge, and two reported moderate knowledge. Only one study specified a moderately high level of knowledge of HPV vaccine.

Willingness and Acceptability of HPV Vaccine and Cervical Cancer Screening

Categories of willingness varied across studies: willingness to recommend HPV vaccine (five studies); willingness to get vaccinated (four); willingness to get daughter vaccinated (four); willingness to participate in vaccine trials (one); “interest” in the vaccine for daughters (one); and “interest in learning more about the vaccine” (one). All studies reported high rates of willingness in their respective categories. Twelve studies examined acceptability levels of HPV vaccine and one study examined acceptability of cervical cancer screening (Table 1). All 12 studies reported high levels of acceptability of HPV vaccine. However, multiple levels of acceptability were found within the studies because some assessed and compared different vaccine delivery strategies within and in different countries.

Strategies and Factors for Increasing Awareness and Acceptability of HPV Vaccine

Of the 27 studies, 26 discussed strategies for vaccination and increasing awareness. Studies in the six countries in the review where HPV vaccination pilot programs were conducted discussed the implementation strategies used for vaccination while the remaining countries in this review discussed recommended strategies for implementation. Rwanda, South Africa Tanzania and Uganda used school-based strategies achieving 93.2%, 97.8%, 71.6% and 88.9% vaccine uptake, respectively [25], [28]. Lesotho used a mixed vaccination strategy (clinic and school-based) [30]. Cameroon used three distinct approaches to deliver vaccines namely school-based, health facilities and community outreach programs in churches and mother-to-daughter [15], [17], [18]. In addition, all studies, with the exception of Lesotho specifically mentioned that sensitization campaigns were used in their vaccination strategies [30]. Rwanda conducted a nationwide campaign while South Africa, Tanzania, Cameroon and Uganda conducted focused educational campaigns to targeted groups [15], [25], [28], [29], [31]. Two studies in both Botswana [40] and Ghana [41] recommended schools as the ideal venue for HPV vaccine delivery.

Education for increasing awareness was a strong theme throughout the majority of studies. Recommended strategies to implement sensitization programs included community health education programs, continuing medical education for nurses, midwives, doctors and other healthcare workers, and health promotion and policy programs including awareness through social and mass media (i.e. public radio, television and folk media).

Factors influencing acceptability also varied. Twelve studies addressed reasons for acceptability of HPV vaccine. Two studies in Nigeria [42], [43] discussed reasons for rejection among nurses and university students while one study in Tanzania [29] noted that head teachers at three private schools would not permit vaccination, fearing negative parental feedback. In Nigeria [43], nurses' reasons included: insufficient knowledge about HPV vaccine; girls were too young and not sexually active; girls are not yet at risk to HPV infections; and it encourages promiscuity. In addition, university students who rejected the HPV vaccine based their decisions on fear of side effects, fear of the unknown, and controversies surrounding the vaccine [42]. Themes surrounding acceptability included access to the vaccine, side effects and effectiveness, protection against and prevention of cervical cancer, provider and teacher recommendations, support from the National Immunization Program and cost [42], [43].

GAVI Alliance Eligibility Based on DTP3 Levels and Pilot Demonstration Projects on HPV Vaccine Delivery

Of the 13 countries included in this review, 12 have achieved 70% coverage or higher of the DTP3 vaccine since 2003, one of GAVI Alliance's criteria for vaccine support; the exception is Nigeria (Table 3). Six of those countries had an HPV vaccination pilot program (Cameroon, Lesotho, Rwanda, South Africa, Tanzania and Uganda). There were 31 sub-Saharan African countries not included in the review because there were no studies based in these countries that met the inclusion criteria. The majority of these countries did not start consistently reaching coverage levels of 70% or higher until 2005 (Table 4). From 2008 through 2011, all countries, with the exception of Mauritania, have maintained coverage at 70% or above (Table 4).

thumbnail
Table 3. Reported Estimates of DTP3 Coverage in sub-Saharan Countries included in this review.

doi:10.1371/journal.pone.0090912.t003

thumbnail
Table 4. Reported Estimates of DTP3 Coverage in Countries Not Included in the Review.

doi:10.1371/journal.pone.0090912.t004

Discussion

This review identified low levels of knowledge and mixed levels of awareness on cervical cancer, HPV and HPV vaccine, and high levels of acceptability of HPV vaccine among all key demographics. In particular, high acceptability of HPV vaccine despite the lack of knowledge about cervical cancer and HPV represents an opportunity for increased education and awareness strategies about cervical cancer, HPV and HPV vaccine. This is important to help key demographics understand the transmission of HPV, its characteristics and associated risks [17], [44], and the benefits of HPV vaccine.

Engaging all key demographics through improved and increased education will elevate public trust, which is a critical component of successful implementation of widespread vaccine coverage. Incidences such as those seen in Japan, India and Rwanda [26], [27], [34], have challenged public trust in HPV vaccines. Additionally, the qualitative insight provided by this review shows that factors influencing acceptability are often tied to issues of public trust, such as concerns over side effects and safety. This is not only a concern in low- and mid-income countries. For instance, Japan's Ministry of Health recently withdrew its recommendation for administering HPV vaccine because of reports of side effects, although it still pays for the vaccine for parents consenting to immunize their daughters [34].

Anti-vaccination groups frequently post inaccurate information about vaccine side effects on the web, which is publicized by both local and national media [46], [47]. These examples indicate the need to constantly engage and educate the public to avoid the risk of health programs failing [48], [49]. While it may not be advisable or possible to respond to all such misinformation, it is essential to counteract it by providing scientifically correct information in a proactive manner so people will seek appropriate medical advice for clarification [50].

Tailored community-based interventions and sensitization programs are a viable means to achieve this for multiple reasons. They have the potential to curb concerns about safety and effectiveness of the vaccine while dispelling negative myths or controversies [45]. Specific training for healthcare workers, the first contact point for patients, will provide them with the accurate knowledge and information necessary to discuss cervical cancer, HPV and HPV vaccine with their patients as well as the ability to properly detect, screen and test for HPV and cervical cancer [18], [43].

In addition to understanding levels of knowledge, awareness and acceptability, this review uncovered encouraging trends concerning SSA countries' eligibility for GAVI Alliance support. Only six countries have currently met the two criteria required by the GAVI Alliance to support introduction of the HPV vaccine at a lower cost of US$4.50 per dose [21]. Of the six, Rwanda has already achieved 93.2% vaccine coverage among girls in grade six and is taking the lead to enroll all eligible girls for HPV vaccination through GAVI alliance support in 2014.

Further, our analysis of national vaccine coverage for DTP3 in SSA shows rapid expansion from just one country reaching 80% in 1980 to 35 countries in 2010 [6]. Of the 31 countries that did not meet the review inclusion criteria, only Mauritania did not consistently achieve GAVI Alliance's eligibility criteria requiring DTP3 coverage levels greater than or equal to 70% (Table 4). Of the countries included in this review, only Nigeria failed to meet this threshold. The challenges in Nigeria are perhaps unique especially in the context of the recent polio vaccine boycott and killings [51]. This calls for interrogating vaccine acceptance determinants using, for instance, the health-belief model [45] and addressing these through a re-emphasis on contextualized public communication and education to mitigate resistance and to build trust [6].

Such consistently high DTP3 coverage levels among the majority of SSA countries indicates structural health system capabilities to deliver simple vaccines to the population [1], [3]. This further demonstrates the feasibility for these countries to deliver multi-dose vaccines, such as HPV, for 50% of a target vaccination cohort in an average size district, which would qualify them for GAVI Alliance support. Support from GAVI Alliance is a critical and essential gateway to preventing cervical cancer through vaccination in SSA and bridging the global cancer divide [5].

As this review shows, engaging all stakeholders at multiple levels in countries that meet these requirements is necessary for successful HPV vaccine implementation. Governments should leverage the high levels of acceptability and willingness to vaccinate by increasing education for healthcare workers, women/girls and parents/guardians. Governments should also determine appropriate strategies for disseminating information and vaccine delivery by building upon current infrastructures, such as existing EPIs and school-based programs. This has been shown to be an effective approach because it relies on the involvement of multiple critical stakeholders from the government down to the community level, as seen in Rwanda, South Africa, Uganda and Tanzania [2], [6], [25], [26], [28], [31]. Tailored community-based sensitization campaigns aimed at a targeted population, as used in Cameroon, also proved effective [15], [17], [18]. Thus, using hybrid delivery system models may be more beneficial as per country experiences in the EPI and can help inform and determine best practices when developing HPV vaccine pilot programs [4], [6].

Conclusions

The objective of this study was to provide a systematic review of knowledge and awareness of HPV vaccine, willingness to vaccinate, and acceptability of the vaccine, as well as fulfillment of GAVI Alliance's eligibility criteria for vaccine assistance in SSA. To the best of our knowledge, this is the first systematic review of the potential readiness for introduction of HPV vaccine in the sub-continent. Examining the region collectively offers insight into its readiness and ability to implement HPV vaccination on a broader scale while shedding light on the successes, challenges, and lessons of implementation.

From this review, three important themes have emerged. (1) There are high levels of acceptability and willingness to vaccinate. These should be harnessed by national governments to establish and implement HPV vaccination strategies that build upon existing infrastructures. (2) Overall, six SSA countries qualify for GAVI Alliance assistance to introduce HPV vaccine at a national level. (3) Lastly, there is a need for increased education and awareness among all three key demographics about HPV, HPV vaccine and the burden of cervical cancer as a disease.

The combination of required DTP3 coverage, high acceptability of HPV vaccine and high willingness to vaccinate, indicates the readiness and potential for SSA countries to introduce HPV vaccine to the population. Successfully doing so will depend on implementing tailored delivery strategies that fit each country's needs and engaging the government at all levels. Building upon the lessons learned from GAVI Alliance eligible SSA countries will pave the way for those SSA countries still working to meet the criteria. These countries should also take advantage of and benefit from the “decade of vaccines” and the GIVS when there is a re-dedication by donors to meet these goals [4], [6].

Limitations

There were some limitations in this review. The studies reviewed lacked consistency in regards to psychometric characteristics used. Not all of the studies used a theoretical framework, consistent labeling of themes examined, or rigorous testing and validation of the measures as previously outlined [52]. While some assessed levels of knowledge and awareness of cervical cancer and HPV, others did not. Still others discussed levels of willingness to vaccinate and acceptability of HPV vaccine while others did not. Some studies discussed all themes. This indicates a need for more standardized methods on awareness and knowledge of HPV and HPV vaccine, and acceptability and willingness to vaccinate to provide better insight to guide health care practitioners in developing successful community and clinical interventions and scaling up HPV vaccination. Every effort was made to include all studies but it is possible some were missed.

Supporting Information

Figure S1.

Flow Chart Diagram.

doi:10.1371/journal.pone.0090912.s001

(TIFF)

Table S1.

Quality appraisal of qualitative studies.

doi:10.1371/journal.pone.0090912.s002

(DOCX)

Table S2.

Quality assessment of surveys.

doi:10.1371/journal.pone.0090912.s003

(DOCX)

Checklist S1.

PRISMA Checklist

doi:10.1371/journal.pone.0090912.s004

(DOC)

Appendix S1.

Search strategies for bibliographic databases.

doi:10.1371/journal.pone.0090912.s005

(DOCX)

Author Contributions

Conceived and designed the experiments: JGO SP RW PAB EW TW. Analyzed the data: JGO SP. Wrote the paper: JGO SP RW PAB EW TW.

References

  1. 1. Chauke-Moagi BE, Mumba M (2012) New vaccine introduction in the East and Southern African sub-region of the WHO African region in the context of GIVS and MDGs. Vaccine 30: C3–C8. doi: 10.1016/j.vaccine.2012.05.086
  2. 2. Levine OS, Bloom DE, Cherian T, de Quadros C, Sow S, et al. (2011) The future of immunisation policy, implementation, and financing. The Lancet 378: 439–448. doi: 10.1016/s0140-6736(11)60406-6
  3. 3. WHO (2012) WHO and UNICEF. Progress towards global immunization goals – 2011. Geneva: World Health Organization. 35 p. p.
  4. 4. Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, et al. (2011) During the ‘decade of vaccines,’ the lives of 6.4 million children valued at $231 billion could be saved. Health Affairs 30: 1010–1020. doi: 10.1377/hlthaff.2011.0381
  5. 5. Knaul FM, Frenk J, Shulman L (2011) Global Task Force on Expanded Access to cancer care and control in developing countries.
  6. 6. Machingaidze S, Wiysonge CS, Hussey GD (2013) Strengthening the Expanded Programme on Immunization in Africa: Looking beyond 2015. PLoS medicine 10: e1001405. doi: 10.1371/journal.pmed.1001405
  7. 7. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. International journal of cancer 118: 3030–3044. doi: 10.1002/ijc.21731
  8. 8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer 127: 2893–2917. doi: 10.1002/ijc.25516
  9. 9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69–90. doi: 10.3322/caac.20107
  10. 10. Markowitz LE, Dunne E, Saraiya M, Lawson H, Chesson H, et al. (2007) Quadrivalent human papillomavirus vaccine. Morbidity and Mortality weekly report 56: 1–24.
  11. 11. Agosti JM, Goldie SJ (2007) Introducing HPV vaccine in developing countries-key challenges and issues. New England Journal of Medicine 356: 1908–1910. doi: 10.1056/nejmp078053
  12. 12. Gakidou E, Nordhagen S, Obermeyer Z (2008) Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS medicine 5: e132. doi: 10.1371/journal.pmed.0050132
  13. 13. Sitas F, Parkin M, Chirenje Z, Stein L, Mqoqi N, et al. (2006) Disease and mortality in sub-Saharan Africa. World Bank-free PDF
  14. 14. Francis SA, Nelson J, Liverpool J, Soogun S, Mofammere N, et al. (2010) Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa. Vaccine 28: 8026–8032. doi: 10.1016/j.vaccine.2010.08.090
  15. 15. Ayissi CA, Wamai RG, Oduwo GO, Perlman S, Welty E, et al. (2012) Awareness, Acceptability and Uptake of Human Papilloma Virus Vaccine Among Cameroonian School-Attending Female Adolescents. Journal of community health 37: 1127–1135. doi: 10.1007/s10900-012-9554-z
  16. 16. Chan ZC, Chan TS, Ng KK, Wong ML (2012) A Systematic Review of Literature about Women's Knowledge and Attitudes toward Human Papillomavirus (HPV) Vaccination. Public Health Nursing 29: 481–489. doi: 10.1111/j.1525-1446.2012.01022.x
  17. 17. Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, et al. (2012) Assessing the effectiveness of a community-based sensitization strategy in creating awareness about HPV, cervical cancer and HPV vaccine among parents in North West Cameroon. Journal of community health 37: 917–926. doi: 10.1007/s10900-012-9540-5
  18. 18. Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, et al. (2013) Awareness, knowledge and beliefs about HPV, cervical cancer and HPV vaccines among nurses in Cameroon: an exploratory study. Int J Nurs Stud 50: 1399–1406. doi: 10.1016/j.ijnurstu.2012.12.020
  19. 19. Louie KS, De Sanjose S, Mayaud P (2009) Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Tropical Medicine & International Health 14: 1287–1302. doi: 10.1111/j.1365-3156.2009.02372.x
  20. 20. WHO (2009) Human papillomavirus vaccines. WHO position paper. 118–131 p.
  21. 21. Youngblood R (2013) GAVI injects new life into HPV vaccine rollout. Lancet 381: 1688. doi: 10.1016/s0140-6736(13)61058-2
  22. 22. GAVI (2011) GAVI welcomes lower prices for life-saving vaccines.[press release], June 6, 2011.
  23. 23. Agosti JM, Goldie SJ (2007) Introducing HPV vaccine in developing countries—key challenges and issues. New England Journal of Medicine 356: 1908–1910. doi: 10.1056/nejmp078053
  24. 24. Wigle J, Coast E, Watson-Jones D (2013) Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects. Vaccine doi: 10.1016/j.vaccine.2013.06.016
  25. 25. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, et al. (2012) Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bulletin of the World Health Organization 90: 623–628. doi: 10.2471/blt.11.097253
  26. 26. Binagwaho A, Wagner CM, Nutt CT (2011) HPV vaccine in Rwanda: different disease, same double standard. The Lancet 378: 1916. doi: 10.1016/s0140-6736(11)61837-0
  27. 27. Ouedraogo N, Müller O, Jahn A, Gerhardus A (2011) Human papillomavirus vaccination in Africa. The Lancet 378: 315–316. doi: 10.1016/s0140-6736(11)61164-1
  28. 28. LaMontagne DS, Barge S, Thi Le N, Mugisha E, Penny ME, et al. (2011) Human papillomavirus vaccine delivery strategies that achieved high coverage in low-and middle-income countries. Bulletin of the World Health Organization 89: 821–830. doi: 10.2471/blt.11.08986
  29. 29. Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, et al. (2012) Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. Journal of Infectious Diseases 206: 678–686. doi: 10.1093/infdis/jis407
  30. 30. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, et al. (2012) Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health 12: 370. doi: 10.1186/1471-2458-12-370
  31. 31. Moodley I, Tathiah N, Mubaiwa V, Denny L (2013) High uptake of Gardasil vaccine among 9–12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal, South Africa. SAMJ: South African Medical Journal 103: 313–317. doi: 10.7196/samj.6414
  32. 32. Anorlu RI (2008) Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters 16: 41–49. doi: 10.1016/s0968-8080(08)32415-x
  33. 33. Ebosse Y (2010) Mama Fouda authorizes a vaccine that kills. Le Soir Hebd. Yaounde, Cameroon: The Evening Weekly.
  34. 34. Gilmour S, Kanda M, Kusumi E, Tanimoto T, Kami M, et al. (2013) HPV vaccination programme in Japan. The Lancet 382: 768. doi: 10.1016/s0140-6736(13)61831-0
  35. 35. Larson HJ, Brocard P, Garnett G (2010) The India HPV-vaccine suspension. The Lancet 376: 572–573. doi: 10.1016/s0140-6736(10)60881-1
  36. 36. Khan KS, Ter Riet G, Glanville J, Sowden AJ, Kleijnen J (2001) Undertaking systematic reviews of research on effectiveness: CRD's guidance for carrying out or commissioning reviews: NHS Centre for Reviews and Dissemination.
  37. 37. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine 151: 264–269. doi: 10.7326/0003-4819-151-4-200908180-00135
  38. 38. Tan TP, Stokes T, Shaw EJ (2009) Use of qualitative research as evidence in the clinical guideline program of the National Institute for Health and Clinical Excellence. International Journal of Evidence-Based Healthcare 7: 169–172. doi: 10.1111/j.1744-1609.2009.00135.x
  39. 39. Petticrew M, Roberts H (2008) Systematic reviews in the social sciences: A practical guide: Wiley. com.
  40. 40. DiAngi YT, Panozzo CA, Ramogola-Masire D, Steenhoff AP, Brewer NT (2011) A cross-sectional study of HPV vaccine acceptability in Gaborone, Botswana. PloS one 6: e25481. doi: 10.1371/journal.pone.0025481
  41. 41. Coleman MA, Levison J, Sangi-Haghpeykar H (2011) HPV vaccine acceptability in Ghana, West Africa. Vaccine 29: 3945–3950. doi: 10.1016/j.vaccine.2011.03.093
  42. 42. Iliyasu Z, Abubakar I, Aliyu M, Galadanci H (2010) Cervical cancer risk perception and predictors of human papilloma virus vaccine acceptance among female university students in northern Nigeria. Journal of Obstetrics & Gynaecology 30: 857–862. doi: 10.3109/01443615.2010.511724
  43. 43. Makwe CC, Anorlu RI (2011) Knowledge of and attitude toward human papillomavirus infection and vaccines among female nurses at a tertiary hospital in Nigeria. International journal of women's health 3: 313. doi: 10.2147/ijwh.s22792
  44. 44. Mingo AM, Panozzo CA, DiAngi YT, Smith JS, Steenhoff AP, et al. (2012) Cervical cancer awareness and screening in Botswana. Int J Gynecol Cancer 22: 638–644. doi: 10.1097/igc.0b013e318249470a
  45. 45. Omer SB, Orenstein WA, Koplan JP (2013) Go Big and Go Fast—Vaccine Refusal and Disease Eradication. New England Journal of Medicine 368: 1374–1376. doi: 10.1056/nejmp1300765
  46. 46. Crowcroft NS, McKenzie KJ (2013) Inoculating communities against vaccine scare stories. Lancet Infect Dis 13: 564–565. doi: 10.1016/s1473-3099(13)70131-2
  47. 47. Bean SJ (2011) Emerging and continuing trends in vaccine opposition website content. Vaccine 29: 1874–1880. doi: 10.1016/j.vaccine.2011.01.003
  48. 48. Larson HJ, Heymann DL (2010) Public health response to influenza A (H1N1) as an opportunity to build public trust. JAMA: The Journal of the American Medical Association 303: 271–272. doi: 10.1001/jama.2009.2023
  49. 49. Paterson P, Larson HJ (2012) The role of publics in the introduction of new vaccines. Health policy and planning 27: ii77–ii79. doi: 10.1093/heapol/czs038
  50. 50. Larson HJ, Smith DM, Paterson P, Cumming M, Eckersberger E, et al. (2013) Measuring vaccine confidence: analysis of data obtained by a media surveillance system used to analyse public concerns about vaccines. Lancet Infect Dis 13: 606–613. doi: 10.1016/s1473-3099(13)70108-7
  51. 51. Friedrich M (2013) Killings in Nigeria. JAMA 309: 1101–1101. doi: 10.1001/jama.2013.2400
  52. 52. Allen JD, Coronado GD, Williams RS, Glenn B, Escoffery C, et al. (2010) A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability. Vaccine 28: 4027–4037. doi: 10.1016/j.vaccine.2010.03.063
  53. 53. Liu FW, Vwalika B, Hacker MR, Allen S, Awtrey CS (2012) Cervical Cancer and HPV Vaccination: Knowledge and Attitudes of Adult Women in Lusaka, Zambia. Journal of Vaccines & Vaccination doi: 10.4172/2157-7560.1000138
  54. 54. Remes P, Selestine V, Changalucha J, Ross D, Wight D, et al. (2012) A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine doi: 10.1016/j.vaccine.2012.06.025
  55. 55. Ugwu EO, Obi SN, Ezechukwu PC, Okafor II, Ugwu AO (2013) Acceptability of human papilloma virus vaccine and cervical cancer screening among female health-care workers in Enugu, Southeast Nigeria. Niger J Clin Pract 16: 249–252. doi: 10.4103/1119-3077.110141
  56. 56. Mupepi SC, Sampselle CM, Johnson TR (2011) Knowledge, attitudes, and demographic factors influencing cervical cancer screening behavior of Zimbabwean women. Journal of Women's Health 20: 943–952. doi: 10.1089/jwh.2010.2062
  57. 57. McCarey C, Pirek D, Tebeu P, Boulvain M, Doh A, et al. (2011) Awareness of HPV and cervical cancer prevention among Cameroonian healthcare workers. BMC women's health 11: 45. doi: 10.1186/1472-6874-11-45
  58. 58. Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, et al. (2013) Awareness, knowledge and beliefs about HPV, cervical cancer and HPV vaccines among nurses in Cameroon: An exploratory study. International journal of nursing studies doi: 10.1016/j.ijnurstu.2012.12.020
  59. 59. Rositch AF, Gatuguta A, Choi RY, Guthrie BL, Mackelprang RD, et al. (2012) Knowledge and acceptability of pap smears, self-sampling and HPV vaccination among adult women in Kenya. PLoS One 7: e40766. doi: 10.1371/journal.pone.0040766
  60. 60. Poole D, Tracy K, Levitz L, Yekta S, Kossow E, et al. (2012) Knowledge/attitude/practices of HPV & cervical cancer, willingness to participate in vaccine trial in preparation for HIV & HPV vaccine trials in Mali. Retrovirology 9: O27. doi: 10.1186/1742-4690-9-s2-o27
  61. 61. Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS (2010) HPV vaccine acceptability among Kenyan women. Vaccine 28: 4864–4867. doi: 10.1016/j.vaccine.2010.05.034
  62. 62. Nelson JA, Francis SA, Liverpool J, Soogun S, Mofammere N (2010) Healers in a non-traditional role; a focus group study of Sangoma's knowledge of and attitudes to cervical cancer prevention and screening in Johannesburg, South Africa. Sexual & Reproductive Healthcare 1: 195–196. doi: 10.1016/j.srhc.2010.07.004
  63. 63. Maher D, Ford N, Unwin N (2012) Priorities for developing countries in the global response to non-communicable diseases. Globalization and Health 8: 1–8. doi: 10.1186/1744-8603-8-14
  64. 64. Urasa M, Darj E (2011) Knowledge of cervical cancer and screening practices of nurses at a regional hospital in Tanzania. African health sciences 11.
  65. 65. Mbamara SU, Ikpeze OC, Okonkwo J, Onyiaorah IV, Ukah CO (2011) Knowledge, attitude and practice of cervical cancer screening among women attending gynecology clinics in a tertiary level medical care center in southeastern Nigeria. The Journal of reproductive medicine 56: 491–496.
  66. 66. Francis SA, Battle-Fisher M, Liverpool J, Hipple L, Mosavel M, et al. (2011) A qualitative analysis of South African women's knowledge, attitudes, and beliefs about HPV and cervical cancer prevention, vaccine awareness and acceptance, and maternal-child communication about sexual health. Vaccine 29: 8760–8765. doi: 10.1016/j.vaccine.2011.07.116
  67. 67. Morhason-Bello I, Oladokun A, Adedokun B, Adesina O, Awolude O, et al. (2009) Introduction of human papilloma virus vaccine in a low resource setting: a survey of the views of Nigerian gynaecologists. International Journal of Gynecology & Obstetrics 107: S274. doi: 10.1016/s0020-7292(09)61010-9
  68. 68. Watson-Jones D, Tomlin K, Remes P, Baisley K, Ponsiano R, et al. (2012) Reasons for Receiving or Not Receiving HPV Vaccination in Primary Schoolgirls in Tanzania: A Case Control Study. PLoS One 7: e45231. doi: 10.1371/journal.pone.0045231
  69. 69. Galagan SR, Paul P, Menezes L, LaMontagne DS (2013) Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam. Vaccine doi: 10.1016/j.vaccine.2013.04.056
  70. 70. Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbidde EK (2012) Universal routine HPV vaccination for young girls in Uganda: a review of opportunities and potential obstacles. Infectious agents and cancer 7: 24. doi: 10.1186/1750-9378-7-24